Clinical Trial Update: Prospective Evaluation of Imaging Response Biomarkers During [177Lu]Lu-PSMA in Metastatic Castration-resistant Prostate Cancer

View source ↗

Summary

This clinical trial update describes a prospective study evaluating imaging response biomarkers during [177Lu]Lu-PSMA therapy in metastatic castration-resistant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Pluvicto (177Lu-PSMA-617) (lutetium-177 PSMA-617)

Snippet

Sponsor: University Hospital, Grenoble | Conditions: Prostate Cancer Metastatic Disease | Status: RECRUITING